Clinical Trials List
2020-03-01 - 2026-12-31
Phase I
Recruiting2
ICD-10D00.00
Carcinoma in situ of oral cavity, unspecified site
ICD-10D00.01
Carcinoma in situ of labial mucosa and vermilion border
ICD-10D00.02
Carcinoma in situ of buccal mucosa
ICD-10D00.03
Carcinoma in situ of gingiva and edentulous alveolar ridge
ICD-10D00.04
Carcinoma in situ of soft palate
ICD-10D00.05
Carcinoma in situ of hard palate
ICD-10D00.06
Carcinoma in situ of floor of mouth
ICD-10D00.07
Carcinoma in situ of tongue
ICD-10D00.08
Carcinoma in situ of pharynx
ICD-9230.0
Carcinoma in situ of lip, oral cavity and pharynx
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/03/01
Investigators and Locations
Co-Principal Investigator
- 廖斌志 Division of Hematology & Oncology
- 陳冠宇 Division of General Internal Medicine
- 蔡子修 Division of General Internal Medicine
- Chia-Chi Lin Division of Hematology & Oncology
- Chong-Jen Yu Division of General Internal Medicine
- 廖唯昱 Division of General Internal Medicine
- 吳尚俊 Division of General Internal Medicine
- Jih-Hsiang Lee Division of Hematology & Oncology
- JIN-YUAN SHIH Division of General Internal Medicine
- 許嘉林 Division of General Internal Medicine
- YEN-TING LIN Division of General Internal Medicine
- 徐偉勛 Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- 楊景堯 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- JENG-SEN TSENG Division of Thoracic Medicine
- YEN-HSIANG HUANG Division of Thoracic Medicine
- KUO-HSUAN HSU Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
6 participants
-
Global
6-12 participants
